Moderna Chalks Up Industry Milestone With mRNA Cancer Vaccine Efficacy Success

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.

Moderna
Moderna gets key data for its personalized cancer vaccine • Source: Shutterstock

Moderna, Inc. and Merck & Co., Inc.'s success with an mRNA-based cancer vaccine in a Phase IIb trial could form the starting point for a broad new cancer franchise. The companies reported that a Phase IIb study in post-surgical stage III/IV melanoma patients yielded a 44% lower risk of recurrence or death for a combination of Moderna’s experimental mRNA personalized cancer vaccine and Keytruda versus Keytruda monotherapy.

The two companies plan to discuss next steps with the US Food and Drug Administration and hope to initiate a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D